Loading...
ProKidney Corp.
PROK•NASDAQ
HealthcareBiotechnology
$0.98
$0.19(24.22%)
ProKidney Corp. (PROK) Company Profile & Overview
Explore ProKidney Corp.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
ProKidney Corp. (PROK) Company Profile & Overview
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
SectorHealthcare
IndustryBiotechnology
CEODr. Bruce Culleton M.D.
Contact Information
Company Facts
204 Employees
IPO DateJun 30, 2021
CountryUS
Actively Trading